

Company Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

Cellecstar Initiates Pivotal Trial of CLR 131 in Waldenstrom's Macroglobulinemia

Jan 12 2021, 8:30 AM EST

Cellecstar Biosciences Announces Closing of \$24.5 Million Underwritten Public Offering and \$20.5 Million Concurrent Private Placement

Dec 28 2020, 4:05 PM EST

Cellecstar Biosciences Announces Pricing of \$24.5 Million Underwritten Public Offering and \$20.5 Million Concurrent Private Placement

Dec 23 2020, 8:38 AM EST

Stock Overview

Symbol	CLRB	LifeSci Advisors
Exchange	Nasdaq	Monique Kosse
Market Cap	89m	Managing Director
Last Price	\$1.96	T: 212-915-3820
52-Week	\$1.01 - \$3.33	monique@lifesciadvisors.com

01/19/2021 04:00 PM EST

Investor Relations

Management Team

James Caruso

President, CEO and Director

Dov Elefant

Vice President and Chief Financial Officer

Dr. John Friend

Chief Medical Officer

Jarrod Longcor

Chief Business Officer

Cellecstar Biosciences, Inc.

100 Campus Drive, Suite 207
Florham Park, NJ 07932

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.